EMA to deliver verdict on Pfizer BioNTech vaccine today

  •   21/12/2020 - 13h58
  •   HARMANT Adeline

It's a big day for the candidate vaccine developed by Pfizer and BioNTech. Indeed, the European Medicines Agency is currently examining the case of the candidate vaccine from these two laboratories on Monday 21 December. This vaccine is already authorized in the United States and the United Kingdom, where vaccination campaigns have already begun.

72% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Trade CFDs with Plus500
EMA to deliver verdict on Pfizer BioNTech vaccine today

A start of vaccination in January in Europe?

The question that everyone is asking at this stage is, of course, the date of the start of vaccination against Covid-19 in Europe. The answer will be given by the European Medicines Agency or EMA, which is the authority in charge of deciding on the possibility of starting to use this vaccine from Pfizer and BioNTech. The announcement of the EMA's decision is expected to be made later that day.

It should also be recalled that the review of the vaccine by the European Medicines Agency was previously scheduled for 29 December but has finally been completed.the review of the vaccine by the European Medicines Agency was previously scheduled for 29 December but has now been brought forward by a week, which would make it possible to start vaccinating all EU countries on 27 December.

EMA Director General Emer Cook said last week: "We were able to review the schedule for evaluating the anti-Covid-19 vaccines thanks to the incredible efforts of everyone involved in these checks".


What is now known about the efficacy of this vaccine:

This comes as vaccination campaigns have already started in the UK and the US last week. On the European side, the drug agency wanted to put an end to the impatience of the EU countries by indicating that it would only decide once the data had been provided.s quality, safety and efficacy are sufficiently robust and complete to determine whether the benefits outweigh the risks.

At this point, what is known about this vaccine from Pfizer and BioNTech is that it has an efficacy rate of 95%. It was a collaboration between the US laboratory and the German biotech company that this vaccine was developed. It will also be the very first to be marketed to combat this new coronavirus. This vaccine is also the very first to be examined by the European Medicines Agency.

It should be noted, however, that the European Commission has already signed pre-order contracts with 6 laboratories with the aim of obtaining 200 million doses of vaccine.

Finally, in the event that the committee of the European agency in charge of this evaluation does not allow a final decision to be taken on Monday, another meeting would be scheduled for 29 December, i.e. Tuesday of next week, which would potentially delay the start of vaccinations.